D-Pharm: Exploiting pathological enzymes

Eschewing the traditional path of receptor-targeted drugs - which usually requires disease characterization by specific cellular markers - D-Pharm has created RAP (regulated activation of prodrugs), a technology that enables the selective activation and accumulation of drugs within a disease site without the necessity of known markers.

The company believes that the selective metabolic activation of RAP-modified prodrugs within diseased cells enables

Read the full 611 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE